[{"orgOrder":0,"company":"Wuhan Union Hospital","sponsor":"Sinocelltech Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Ripertamab","moa":"monoclonal antibodies: tumors","graph1":"Immunology","graph2":"Undisclosed","graph3":"Wuhan Union Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Wuhan Union Hospital \/ Sinocelltech Ltd.","highestDevelopmentStatusID":"1","companyTruncated":"Wuhan Union Hospital \/ Sinocelltech Ltd."},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Immunoglobulin","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"National Institutes of Health \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"National Institutes of Health \/ Inapplicable"},{"orgOrder":0,"company":"Direct Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles","moa":"Progenitor cell","graph1":"Immunology","graph2":"Undisclosed","graph3":"Direct Biologics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Direct Biologics \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Direct Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Saskatchewan Health Authority \u2013 Regina Area","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Amoxicillin Trihydrate","moa":"Bacterial penicillin-binding protein","graph1":"Immunology","graph2":"Undisclosed","graph3":"Saskatchewan Health Authority \u2013 Regina Area","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Saskatchewan Health Authority \u2013 Regina Area \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Saskatchewan Health Authority \u2013 Regina Area \/ Inapplicable"},{"orgOrder":0,"company":"Big Bold Health, PBC","sponsor":"TruDiagnostic","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"HTB Rejuvenate","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Big Bold Health, PBC","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Big Bold Health, PBC \/ TruDiagnostic","highestDevelopmentStatusID":"1","companyTruncated":"Big Bold Health, PBC \/ TruDiagnostic"},{"orgOrder":0,"company":"Greenyn Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Dietary Supplement","year":"2023","type":"Inapplicable","leadProduct":"Antrodia Cinnamomea Mycelia","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Greenyn Biotechnology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Greenyn Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Greenyn Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Bio Nature Health","sponsor":"Citruslabs","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"Eye Empower","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Bio Nature Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bio Nature Health \/ Citruslabs","highestDevelopmentStatusID":"1","companyTruncated":"Bio Nature Health \/ Citruslabs"},{"orgOrder":0,"company":"GLSMED Learning Health S.A.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"Glycan","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"GLSMED Learning Health S.A.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"GLSMED Learning Health S.A. \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"GLSMED Learning Health S.A. \/ Inapplicable"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Hofseth BioCare","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Dietary Supplement","year":"2021","type":"Partnership","leadProduct":"DHA","moa":"||DHA level","graph1":"Immunology","graph2":"Undisclosed","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule, Delayed Release","sponsorNew":"Catalent Pharma Solutions \/ Hofseth BioCare","highestDevelopmentStatusID":"1","companyTruncated":"Catalent Pharma Solutions \/ Hofseth BioCare"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Arthritis Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sodium Butyrate","moa":"Cholinesterase; Histone deacetylase 1; (S)-2-haloacid dehalogenase; 2-hydroxy-6-oxo-7-methylocta-2,4-dienoate hydrolase","graph1":"Immunology","graph2":"Undisclosed","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"NYU Langone Health \/ Arthritis Foundation","highestDevelopmentStatusID":"1","companyTruncated":"NYU Langone Health \/ Arthritis Foundation"},{"orgOrder":0,"company":"NuLiv Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"AstraGin","moa":"Bacterial gut","graph1":"Immunology","graph2":"Undisclosed","graph3":"NuLiv Science","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"NuLiv Science \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"NuLiv Science \/ Inapplicable"},{"orgOrder":0,"company":"National Taiwan University Hospital","sponsor":"Microbio","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Probiotic","year":"2021","type":"Inapplicable","leadProduct":"MS-20","moa":"Gut microbiome","graph1":"Immunology","graph2":"Undisclosed","graph3":"National Taiwan University Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"National Taiwan University Hospital \/ Microbio","highestDevelopmentStatusID":"1","companyTruncated":"National Taiwan University Hospital \/ Microbio"},{"orgOrder":0,"company":"Genmab","sponsor":"Tavotek Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"DENMARK","productType":"Undisclosed","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Genmab \/ Tavotek Biotherapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Genmab \/ Tavotek Biotherapeutics"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Argenx","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"JAPAN","productType":"Undisclosed","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Chugai Pharmaceutical \/ Argenx","highestDevelopmentStatusID":"1","companyTruncated":"Chugai Pharmaceutical \/ Argenx"},{"orgOrder":0,"company":"GRO Biosciences","sponsor":"Leaps by Bayer","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"GRO Biosciences","amount2":0.029999999999999999,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0.029999999999999999,"dosageForm":"Oral","sponsorNew":"GRO Biosciences \/ Leaps by Bayer","highestDevelopmentStatusID":"1","companyTruncated":"GRO Biosciences \/ Leaps by Bayer"},{"orgOrder":0,"company":"CSL Behring","sponsor":"SAB Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"CSL Behring \/ SAB Biotherapeutics","highestDevelopmentStatusID":"1","companyTruncated":"CSL Behring \/ SAB Biotherapeutics"},{"orgOrder":0,"company":"Nuvig Therapeutics","sponsor":"Organovo Holdings","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Nuvig Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0.050000000000000003,"dosageForm":"Oral Inhalation","sponsorNew":"Nuvig Therapeutics \/ Organovo Holdings","highestDevelopmentStatusID":"1","companyTruncated":"Nuvig Therapeutics \/ Organovo Holdings"},{"orgOrder":0,"company":"Forward Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Forward Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0.050000000000000003,"dosageForm":"Oral","sponsorNew":"Forward Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"1","companyTruncated":"Forward Therapeutics \/ RA Capital Management"},{"orgOrder":0,"company":"OMass Therapeutics","sponsor":"Syncona Limited","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"OMass Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0.050000000000000003,"dosageForm":"Oral","sponsorNew":"OMass Therapeutics \/ Syncona Limited","highestDevelopmentStatusID":"1","companyTruncated":"OMass Therapeutics \/ Syncona Limited"},{"orgOrder":0,"company":"Camallergy","sponsor":"OnDosis","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Camallergy","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Camallergy \/ OnDosis","highestDevelopmentStatusID":"1","companyTruncated":"Camallergy \/ OnDosis"},{"orgOrder":0,"company":"Yangtze River Pharmaceutical Group","sponsor":"Alvotech","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Yangtze River Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Yangtze River Pharmaceutical Group \/ Alvotech","highestDevelopmentStatusID":"1","companyTruncated":"Yangtze River Pharmaceutical Group \/ Alvotech"},{"orgOrder":0,"company":"Minapharm Pharmaceuticals","sponsor":"Bioventure Healthcare","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"EGYPT","productType":"Undisclosed","year":"2022","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Minapharm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Minapharm Pharmaceuticals \/ Bioventure Healthcare","highestDevelopmentStatusID":"1","companyTruncated":"Minapharm Pharmaceuticals \/ Bioventure Healthcare"},{"orgOrder":0,"company":"London Health Sciences Centre Research Institute (Lawson)","sponsor":"St. Joseph's Health Care London","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"Fecal Microbiota","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"London Health Sciences Centre Research Institute (Lawson)","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"London Health Sciences Centre Research Institute (Lawson) \/ St. Joseph's Health Care London","highestDevelopmentStatusID":"1","companyTruncated":"London Health Sciences Centre Research Institute (Lawson) \/ St. Joseph's Health Care London"},{"orgOrder":0,"company":"Szeged University","sponsor":"Research Centre for Natural Sciences | University of Debrecen Dept. of Rheumatology","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Pyrophosphate","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Szeged University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Szeged University \/ Research Centre for Natural Sciences | University of Debrecen Dept. of Rheumatology","highestDevelopmentStatusID":"1","companyTruncated":"Szeged University \/ Research Centre for Natural Sciences | University of Debrecen Dept. of Rheumatology"},{"orgOrder":0,"company":"HavaH Therapeutics","sponsor":"Clarus Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Hormone","year":"2021","type":"Licensing Agreement","leadProduct":"Testosterone","moa":"||Androgen Receptor","graph1":"Immunology","graph2":"Undisclosed","graph3":"HavaH Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0.01,"dosageForm":"Subcutaneous Implant","sponsorNew":"HavaH Therapeutics \/ Clarus Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"HavaH Therapeutics \/ Clarus Therapeutics"},{"orgOrder":0,"company":"Chinese SLE Treatment And Research Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Bortezomib","moa":"26S proteasome","graph1":"Immunology","graph2":"Undisclosed","graph3":"Chinese SLE Treatment And Research Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Chinese SLE Treatment And Research Group \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Chinese SLE Treatment And Research Group \/ Inapplicable"},{"orgOrder":0,"company":"Supplement Formulators, Inc.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Dietary Supplement","year":"2020","type":"Inapplicable","leadProduct":"Marine Lipid Oil Concentrate","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Supplement Formulators, Inc.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Supplement Formulators, Inc. \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Supplement Formulators, Inc. \/ Inapplicable"},{"orgOrder":0,"company":"Supplement Formulators, Inc.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Dietary Supplement","year":"2021","type":"Inapplicable","leadProduct":"Marine Lipid Oil Concentrate","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Supplement Formulators, Inc.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Supplement Formulators, Inc. \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Supplement Formulators, Inc. \/ Inapplicable"},{"orgOrder":0,"company":"Omeros","sponsor":"Impatients N.V. trading as myTomorrows","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Narsoplimab","moa":"Mannan-binding lectin serine protease 2","graph1":"Immunology","graph2":"Undisclosed","graph3":"Omeros","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Omeros \/ Impatients N.V. trading as myTomorrows","highestDevelopmentStatusID":"1","companyTruncated":"Omeros \/ Impatients N.V. trading as myTomorrows"},{"orgOrder":0,"company":"University of California, San Diego","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Undisclosed","graph3":"University of California, San Diego","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of California, San Diego \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"1","companyTruncated":"University of California, San Diego \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Immunology","graph2":"Undisclosed","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Enzene Biosciences","sponsor":"Theramex","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"INDIA","productType":"Antibody","year":"2021","type":"Agreement","leadProduct":"Tocilizumab","moa":"||Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Undisclosed","graph3":"Enzene Biosciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Pre-Filled Injection","sponsorNew":"Enzene Biosciences \/ Theramex","highestDevelopmentStatusID":"1","companyTruncated":"Enzene Biosciences \/ Theramex"},{"orgOrder":0,"company":"Universidad de la Sabana","sponsor":"Fundaci\u00f3n Neumologica Colombiana | Innocell SAS | Stem Medicina Regenerativa","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Mesenchymal Stem Cell","moa":"Stem cell proliferation","graph1":"Immunology","graph2":"Undisclosed","graph3":"Universidad de la Sabana","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Universidad de la Sabana \/ Fundaci\u00f3n Neumologica Colombiana | Innocell SAS | Stem Medicina Regenerativa","highestDevelopmentStatusID":"1","companyTruncated":"Universidad de la Sabana \/ Fundaci\u00f3n Neumologica Colombiana | Innocell SAS | Stem Medicina Regenerativa"},{"orgOrder":0,"company":"Hope Biosciences","sponsor":"Hope Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"HB-adMSC","moa":"Mesenchymal stem cells","graph1":"Immunology","graph2":"Undisclosed","graph3":"Hope Biosciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hope Biosciences \/ Hope Biosciences","highestDevelopmentStatusID":"1","companyTruncated":"Hope Biosciences \/ Hope Biosciences"},{"orgOrder":0,"company":"Avobis Bio","sponsor":"Alimentiv","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"AVB-114","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Avobis Bio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avobis Bio \/ Alimentiv","highestDevelopmentStatusID":"1","companyTruncated":"Avobis Bio \/ Alimentiv"},{"orgOrder":0,"company":"Tongji Hospital","sponsor":"IASO Bio","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Equecabtagene Autoleucel","moa":"BCMA","graph1":"Immunology","graph2":"Undisclosed","graph3":"Tongji Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tongji Hospital \/ IASO Bio","highestDevelopmentStatusID":"1","companyTruncated":"Tongji Hospital \/ IASO Bio"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Avacta Group","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Cell and Gene therapy","year":"2020","type":"Licensing Agreement","leadProduct":"Mesenchymal Stem Cell","moa":"Stem cell proliferation","graph1":"Immunology","graph2":"Undisclosed","graph3":"Daewoong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Daewoong Pharmaceutical \/ Avacta Group","highestDevelopmentStatusID":"1","companyTruncated":"Daewoong Pharmaceutical \/ Avacta Group"},{"orgOrder":0,"company":"Tract Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"TRK-001","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Tract Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tract Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Tract Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NextEvo Inc.","sponsor":"Atlantia Food Clinical Trials","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Immunology","graph2":"Undisclosed","graph3":"NextEvo Inc.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NextEvo Inc. \/ Atlantia Food Clinical Trials","highestDevelopmentStatusID":"1","companyTruncated":"NextEvo Inc. \/ Atlantia Food Clinical Trials"},{"orgOrder":0,"company":"Raphael Pharma","sponsor":"Citruslabs","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabigerol","moa":"CB1 receptor","graph1":"Immunology","graph2":"Undisclosed","graph3":"Raphael Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Raphael Pharma \/ Citruslabs","highestDevelopmentStatusID":"1","companyTruncated":"Raphael Pharma \/ Citruslabs"},{"orgOrder":0,"company":"The Valens Company","sponsor":"PMI Mexico","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Agreement","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Immunology","graph2":"Undisclosed","graph3":"The Valens Company","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oil","sponsorNew":"The Valens Company \/ PMI Mexico","highestDevelopmentStatusID":"1","companyTruncated":"The Valens Company \/ PMI Mexico"},{"orgOrder":0,"company":"Innocan Pharma","sponsor":"Research Capital Corporation","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Controlled Substance","year":"2023","type":"Private Placement","leadProduct":"Cannabidiol","moa":"||Cannabinoid CB1 receptor","graph1":"Immunology","graph2":"Undisclosed","graph3":"Innocan Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Innocan Pharma \/ Research Capital Corporation","highestDevelopmentStatusID":"1","companyTruncated":"Innocan Pharma \/ Research Capital Corporation"},{"orgOrder":0,"company":"Vitae Health Innovation","sponsor":"Hospital Vall d'Hebron","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Vitae Health Innovation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vitae Health Innovation \/ Hospital Vall d'Hebron","highestDevelopmentStatusID":"1","companyTruncated":"Vitae Health Innovation \/ Hospital Vall d'Hebron"},{"orgOrder":0,"company":"Johns Hopkins University","sponsor":"Abbott Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Dietary Supplement","year":"2020","type":"Inapplicable","leadProduct":"Ensure Enlive","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Johns Hopkins University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johns Hopkins University \/ Abbott Laboratories","highestDevelopmentStatusID":"1","companyTruncated":"Johns Hopkins University \/ Abbott Laboratories"},{"orgOrder":0,"company":"Laval University","sponsor":"Ministry of Agriculture, Fisheries and Food, Quebec | Groupe De Recherche En Rhumatologie Et Maladies Osseuses Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Dietary Supplement","year":"2020","type":"Inapplicable","leadProduct":"Seal Oil","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Laval University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oil","sponsorNew":"Laval University \/ Ministry of Agriculture, Fisheries and Food, Quebec | Groupe De Recherche En Rhumatologie Et Maladies Osseuses Inc.","highestDevelopmentStatusID":"1","companyTruncated":"Laval University \/ Ministry of Agriculture, Fisheries and Food, Quebec | Groupe De Recherche En Rhumatologie Et Maladies Osseuses Inc."},{"orgOrder":0,"company":"Galvani Bioelectronics","sponsor":"NAMSA | Q2 Solutions","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Galvani Bioelectronics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Galvani Bioelectronics \/ NAMSA | Q2 Solutions","highestDevelopmentStatusID":"1","companyTruncated":"Galvani Bioelectronics \/ NAMSA | Q2 Solutions"},{"orgOrder":0,"company":"Universit\u00e9 Libre de Bruxelles","sponsor":"DESCARTES Working Group On Transplantation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Universit\u00e9 Libre de Bruxelles","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Universit\u00e9 Libre de Bruxelles \/ DESCARTES Working Group On Transplantation","highestDevelopmentStatusID":"1","companyTruncated":"Universit\u00e9 Libre de Bruxelles \/ DESCARTES Working Group On Transplantation"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Dietary Supplement","year":"2021","type":"Inapplicable","leadProduct":"Short Chain Fatty Acid","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NYU Langone Health \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"NYU Langone Health \/ Inapplicable"},{"orgOrder":0,"company":"Peter Korsten","sponsor":"DiaMed GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Peter Korsten","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Peter Korsten \/ DiaMed GmbH","highestDevelopmentStatusID":"1","companyTruncated":"Peter Korsten \/ DiaMed GmbH"},{"orgOrder":0,"company":"Hasanuddin University","sponsor":"Arla Foods","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"Milk","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Hasanuddin University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hasanuddin University \/ Arla Foods","highestDevelopmentStatusID":"1","companyTruncated":"Hasanuddin University \/ Arla Foods"},{"orgOrder":0,"company":"Allergy Therapeutics","sponsor":"Ecarf Institute GmbH | Bencard Allergie GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"holoBLG","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Allergy Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allergy Therapeutics \/ Ecarf Institute GmbH | Bencard Allergie GmbH","highestDevelopmentStatusID":"1","companyTruncated":"Allergy Therapeutics \/ Ecarf Institute GmbH | Bencard Allergie GmbH"},{"orgOrder":0,"company":"Prollergy dba Ready Set Food","sponsor":"ObvioHealth","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Prollergy dba Ready Set Food","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Prollergy dba Ready Set Food \/ ObvioHealth","highestDevelopmentStatusID":"1","companyTruncated":"Prollergy dba Ready Set Food \/ ObvioHealth"},{"orgOrder":0,"company":"United Pharmaceuticals","sponsor":"Slb Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JORDAN","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"United Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"United Pharmaceuticals \/ Slb Pharma","highestDevelopmentStatusID":"1","companyTruncated":"United Pharmaceuticals \/ Slb Pharma"},{"orgOrder":0,"company":"Sahlgrenska University Hospital","sponsor":"Calmino group AB","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"Dietary Fiber","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Sahlgrenska University Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sahlgrenska University Hospital \/ Calmino group AB","highestDevelopmentStatusID":"1","companyTruncated":"Sahlgrenska University Hospital \/ Calmino group AB"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"Alfamino Junior","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Nestle Health Sciences SA \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Nestle Health Sciences SA \/ Inapplicable"},{"orgOrder":0,"company":"Chung Shan Medical University","sponsor":"SYNBIO TECH INC. Kaohsiung Taiwan","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"LDL557-HK","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Chung Shan Medical University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chung Shan Medical University \/ SYNBIO TECH INC. Kaohsiung Taiwan","highestDevelopmentStatusID":"1","companyTruncated":"Chung Shan Medical University \/ SYNBIO TECH INC. Kaohsiung Taiwan"},{"orgOrder":0,"company":"Exosomm Ltd.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Dietary Supplement","year":"2025","type":"Inapplicable","leadProduct":"Whey Protein Milk-Derived Exosome","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Exosomm Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Exosomm Ltd. \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Exosomm Ltd. \/ Inapplicable"},{"orgOrder":0,"company":"Innowage Limited","sponsor":"Mettle Networks","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Innowage Limited","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innowage Limited \/ Mettle Networks","highestDevelopmentStatusID":"1","companyTruncated":"Innowage Limited \/ Mettle Networks"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Dietary Supplement","year":"2025","type":"Inapplicable","leadProduct":"EHF","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nestle Health Sciences SA \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Nestle Health Sciences SA \/ Inapplicable"},{"orgOrder":0,"company":"Hospital Universitari Vall d'Hebron Research Institute","sponsor":"Pharma Nord","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Coenzyme Q10","moa":"NADH dehydrogenase [ubiquinone] flavoprotein 3, mitochondrial; Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial","graph1":"Immunology","graph2":"Undisclosed","graph3":"Hospital Universitari Vall d'Hebron Research Institute","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hospital Universitari Vall d'Hebron Research Institute \/ Pharma Nord","highestDevelopmentStatusID":"1","companyTruncated":"Hospital Universitari Vall d'Hebron Research Institute \/ Pharma Nord"},{"orgOrder":0,"company":"Windgap Medical","sponsor":"Taiwania Capital","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2021","type":"Series B Financing","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Undisclosed","graph3":"Windgap Medical","amount2":0.02,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0.02,"dosageForm":"Pre-Filled Injection","sponsorNew":"Windgap Medical \/ Taiwania Capital","highestDevelopmentStatusID":"1","companyTruncated":"Windgap Medical \/ Taiwania Capital"},{"orgOrder":0,"company":"Curexsys Gmbh","sponsor":"Evotec","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Other Large Molecule","year":"2020","type":"Collaboration","leadProduct":"Exosome","moa":"PTEN","graph1":"Immunology","graph2":"Undisclosed","graph3":"Curexsys Gmbh","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Curexsys Gmbh \/ Evotec","highestDevelopmentStatusID":"1","companyTruncated":"Curexsys Gmbh \/ Evotec"},{"orgOrder":0,"company":"University of Glasgow","sponsor":"Kappa Bioscience","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Vitamin K2","moa":"Trypanosoma Cruzipain (Trypano CYSP)","graph1":"Immunology","graph2":"Undisclosed","graph3":"University of Glasgow","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Glasgow \/ Kappa Bioscience","highestDevelopmentStatusID":"1","companyTruncated":"University of Glasgow \/ Kappa Bioscience"},{"orgOrder":0,"company":"Chinese SLE Treatment And Research Group","sponsor":"Shanghai Zhongshan Hospital | Affiliated Hospital of Jilin University, Changchun,China | Second Affiliated Hospital, Nanchang University | The First Affiliated Hospital of Anhui Medical University | Beijing Shijitan Hospital, Capital Medical University | ","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Leflunomide","moa":"Dihydroorotate dehydrogenase","graph1":"Immunology","graph2":"Undisclosed","graph3":"Chinese SLE Treatment And Research Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chinese SLE Treatment And Research Group \/ Shanghai Zhongshan Hospital | Affiliated Hospital of Jilin University, Changchun,China | Second Affiliated Hospital, Nanchang University | The First Affiliated Hospital of Anhui Medical University | Beijing Shijitan Hospital, Capital Medical University | ","highestDevelopmentStatusID":"1","companyTruncated":"Chinese SLE Treatment And Research Group \/ Shanghai Zhongshan Hospital | Affiliated Hospital of Jilin University, Changchun,China | Second Affiliated Hospital, Nanchang University | The First Affiliated Hospital of Anhui Medical University | Beijing Shijitan Hospital, Capital Medical University | "},{"orgOrder":0,"company":"Shandong Qilu Stem Cells Engineering Co., Ltd.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Prednisone","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Undisclosed","graph3":"Shandong Qilu Stem Cells Engineering Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shandong Qilu Stem Cells Engineering Co., Ltd. \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Shandong Qilu Stem Cells Engineering Co., Ltd. \/ Inapplicable"},{"orgOrder":0,"company":"University of Wisconsin, Madison","sponsor":"National Institutes of Health | OnLume | National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Indocyanine Green","moa":"None","graph1":"Immunology","graph2":"Undisclosed","graph3":"University of Wisconsin, Madison","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Wisconsin, Madison \/ National Institutes of Health | OnLume | National Cancer Institute","highestDevelopmentStatusID":"1","companyTruncated":"University of Wisconsin, Madison \/ National Institutes of Health | OnLume | National Cancer Institute"},{"orgOrder":0,"company":"Immunoflex Therapeutics Inc.","sponsor":"Dicentra Inc. | University of British Columbia","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Acetylcysteine","moa":"Glutathione synthetase; Cystine\/glutamate transporter; NAPQI (N-acetyl-p-benzoquinone imine); Aminoacylase-1; Inhibitor of nuclear factor kappa-B kinase subunit beta; Inhibitor of nuclear factor kappa-B kinase subunit alpha; Glutamate receptor ionotropic, NMDA 2B; Glutamate receptor ionotropic, NMDA 1; Glutamate receptor ionotropic, NMDA 2A; Glutamate receptor ionotropic, NMDA 2D; Glutamate receptor ionotropic, NMDA 3A","graph1":"Immunology","graph2":"Undisclosed","graph3":"Immunoflex Therapeutics Inc.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immunoflex Therapeutics Inc. \/ Dicentra Inc. | University of British Columbia","highestDevelopmentStatusID":"1","companyTruncated":"Immunoflex Therapeutics Inc. \/ Dicentra Inc. | University of British Columbia"},{"orgOrder":0,"company":"Epiceutical Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Curcumin","moa":"Albendazole monooxygenase (CYP3A4)","graph1":"Immunology","graph2":"Undisclosed","graph3":"Epiceutical Labs","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Epiceutical Labs \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Epiceutical Labs \/ Inapplicable"},{"orgOrder":0,"company":"Laboratorios Vi\u00f1as, S.A.","sponsor":"Laboratorio Echevarne | Hospital Vall d'Hebron","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Melatonin","moa":"Melatonin receptor","graph1":"Immunology","graph2":"Undisclosed","graph3":"Laboratorios Vi\u00f1as, S.A.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laboratorios Vi\u00f1as, S.A. \/ Laboratorio Echevarne | Hospital Vall d'Hebron","highestDevelopmentStatusID":"1","companyTruncated":"Laboratorios Vi\u00f1as, S.A. \/ Laboratorio Echevarne | Hospital Vall d'Hebron"},{"orgOrder":0,"company":"Jiangxi Provincial People's Hospital","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Immunology","graph2":"Undisclosed","graph3":"Jiangxi Provincial People's Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangxi Provincial People's Hospital \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Jiangxi Provincial People's Hospital \/ Inapplicable"},{"orgOrder":0,"company":"Nantes University Hospital","sponsor":"Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Azathioprine","moa":"DNA | Amidophosphoribosyltransferase","graph1":"Immunology","graph2":"Undisclosed","graph3":"Nantes University Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nantes University Hospital \/ Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives","highestDevelopmentStatusID":"1","companyTruncated":"Nantes University Hospital \/ Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives"},{"orgOrder":0,"company":"National University of Malaysia","sponsor":"HOE Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Elonide","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Undisclosed","graph3":"National University of Malaysia","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"National University of Malaysia \/ HOE Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"National University of Malaysia \/ HOE Pharmaceuticals"},{"orgOrder":0,"company":"Primus Pharmaceutical","sponsor":"KGK Science","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Diosmin","moa":"Aryl hydrocarbon receptor","graph1":"Immunology","graph2":"Undisclosed","graph3":"Primus Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Primus Pharmaceutical \/ KGK Science","highestDevelopmentStatusID":"1","companyTruncated":"Primus Pharmaceutical \/ KGK Science"},{"orgOrder":0,"company":"University of Edinburgh","sponsor":"Cyclacel Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Fadraciclib","moa":"CDK2\/9","graph1":"Immunology","graph2":"Undisclosed","graph3":"University of Edinburgh","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Edinburgh \/ Cyclacel Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"University of Edinburgh \/ Cyclacel Pharmaceuticals"},{"orgOrder":0,"company":"Imcyse","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Peptide","year":"2021","type":"Series B Financing","leadProduct":"Imotope","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Imcyse","amount2":0.029999999999999999,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Imcyse \/ Pfizer Inc","highestDevelopmentStatusID":"1","companyTruncated":"Imcyse \/ Pfizer Inc"},{"orgOrder":0,"company":"University of Exeter","sponsor":"Advanced Growers Limited | Ecog Pro Limited","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Plant Extract\/Herbal","year":"2024","type":"Inapplicable","leadProduct":"Micro-Vegetable Blend","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"University of Exeter","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Exeter \/ Advanced Growers Limited | Ecog Pro Limited","highestDevelopmentStatusID":"1","companyTruncated":"University of Exeter \/ Advanced Growers Limited | Ecog Pro Limited"},{"orgOrder":0,"company":"Hvidovre University Hospital","sponsor":"Chr. Hansen","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Probiotic","year":"2021","type":"Inapplicable","leadProduct":"Bif195","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Hvidovre University Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hvidovre University Hospital \/ Chr. Hansen","highestDevelopmentStatusID":"1","companyTruncated":"Hvidovre University Hospital \/ Chr. Hansen"},{"orgOrder":0,"company":"Chr. Hansen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"Bif-038","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Chr. Hansen","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chr. Hansen \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Chr. Hansen \/ Inapplicable"},{"orgOrder":0,"company":"Wageningen University","sponsor":"Winclove Probiotics B.V. | China Scholarship Council","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"Prebiotic","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Wageningen University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wageningen University \/ Winclove Probiotics B.V. | China Scholarship Council","highestDevelopmentStatusID":"1","companyTruncated":"Wageningen University \/ Winclove Probiotics B.V. | China Scholarship Council"},{"orgOrder":0,"company":"Wecare Probiotics Co., Ltd.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Probiotic","year":"2024","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Immunology","graph2":"Undisclosed","graph3":"Wecare Probiotics Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wecare Probiotics Co., Ltd. \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Wecare Probiotics Co., Ltd. \/ Inapplicable"},{"orgOrder":0,"company":"Wecare Probiotics Co., Ltd.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Probiotic","year":"2024","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Immunology","graph2":"Undisclosed","graph3":"Wecare Probiotics Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wecare Probiotics Co., Ltd. \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Wecare Probiotics Co., Ltd. \/ Inapplicable"},{"orgOrder":0,"company":"Wecare Probiotics Co., Ltd.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Probiotic","year":"2024","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Immunology","graph2":"Undisclosed","graph3":"Wecare Probiotics Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wecare Probiotics Co., Ltd. \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Wecare Probiotics Co., Ltd. \/ Inapplicable"},{"orgOrder":0,"company":"Wecare Probiotics Co., Ltd.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Probiotic","year":"2025","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Immunology","graph2":"Undisclosed","graph3":"Wecare Probiotics Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wecare Probiotics Co., Ltd. \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Wecare Probiotics Co., Ltd. \/ Inapplicable"},{"orgOrder":0,"company":"Wecare Probiotics Co., Ltd.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Probiotic","year":"2025","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Immunology","graph2":"Undisclosed","graph3":"Wecare Probiotics Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wecare Probiotics Co., Ltd. \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Wecare Probiotics Co., Ltd. \/ Inapplicable"},{"orgOrder":0,"company":"Nutricia Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Hydrolyzed Protein","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Nutricia Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nutricia Inc \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Nutricia Inc \/ Inapplicable"},{"orgOrder":0,"company":"Stanford University","sponsor":"Vera Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Protein","year":"2025","type":"Acquisition","leadProduct":"VT-109","moa":"BAFF\/APRIL","graph1":"Immunology","graph2":"Undisclosed","graph3":"Stanford University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stanford University \/ Vera Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Stanford University \/ Vera Therapeutics"},{"orgOrder":0,"company":"Avacta Group","sponsor":"Affyxell Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Protein","year":"2020","type":"Collaboration","leadProduct":"Stefin A","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Avacta Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avacta Group \/ Affyxell Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Avacta Group \/ Affyxell Therapeutics"},{"orgOrder":0,"company":"Sonoma Biotherapeutics","sponsor":"Lyell Immunopharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Sonoma Biotherapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0.040000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Sonoma Biotherapeutics \/ Lyell Immunopharma","highestDevelopmentStatusID":"1","companyTruncated":"Sonoma Biotherapeutics \/ Lyell Immunopharma"},{"orgOrder":0,"company":"Kyverna Therapeutics","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Kyverna Therapeutics","amount2":0.58999999999999997,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0.58999999999999997,"dosageForm":"Undisclosed","sponsorNew":"Kyverna Therapeutics \/ Gilead Sciences","highestDevelopmentStatusID":"1","companyTruncated":"Kyverna Therapeutics \/ Gilead Sciences"},{"orgOrder":0,"company":"Steritas","sponsor":"Argenx","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Steritas","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Steritas \/ Argenx","highestDevelopmentStatusID":"1","companyTruncated":"Steritas \/ Argenx"},{"orgOrder":0,"company":"Beam Therapeutics","sponsor":"Orbital Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Beam Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beam Therapeutics \/ Orbital Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Beam Therapeutics \/ Orbital Therapeutics"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"JAPAN","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Kyowa Kirin","amount2":0.44,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0.44,"dosageForm":"Undisclosed","sponsorNew":"Kyowa Kirin \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"1","companyTruncated":"Kyowa Kirin \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Kyverna Therapeutics","sponsor":"Vida Ventures LLC","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Kyverna Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Kyverna Therapeutics \/ Vida Ventures LLC","highestDevelopmentStatusID":"1","companyTruncated":"Kyverna Therapeutics \/ Vida Ventures LLC"},{"orgOrder":0,"company":"Sanofi","sponsor":"Fidia Farmaceutici Spa","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Undisclosed","year":"2021","type":"Divestment","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Fidia Farmaceutici Spa","highestDevelopmentStatusID":"1","companyTruncated":"Sanofi \/ Fidia Farmaceutici Spa"},{"orgOrder":0,"company":"Mogrify","sponsor":"Sangamo Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Mogrify","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mogrify \/ Sangamo Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Mogrify \/ Sangamo Therapeutics"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Inside Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Undisclosed","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OSE Immunotherapeutics SA \/ Inside Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"OSE Immunotherapeutics SA \/ Inside Therapeutics"},{"orgOrder":0,"company":"Instituto de Investigacion Sanitaria La Fe","sponsor":"Adventia Pharma | Biopolis S.L.","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Peptidic","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Instituto de Investigacion Sanitaria La Fe","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Instituto de Investigacion Sanitaria La Fe \/ Adventia Pharma | Biopolis S.L.","highestDevelopmentStatusID":"1","companyTruncated":"Instituto de Investigacion Sanitaria La Fe \/ Adventia Pharma | Biopolis S.L."},{"orgOrder":0,"company":"ImmuneBiotech Medical Sweden AB","sponsor":"Karolinska Institutet","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Gutmagnific\u2122 H: Gutmagnific","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"ImmuneBiotech Medical Sweden AB","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmuneBiotech Medical Sweden AB \/ Karolinska Institutet","highestDevelopmentStatusID":"1","companyTruncated":"ImmuneBiotech Medical Sweden AB \/ Karolinska Institutet"},{"orgOrder":0,"company":"Edifice Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Iron Bisglycinate Manganese Chloride","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Edifice Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Edifice Health \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Edifice Health \/ Inapplicable"},{"orgOrder":0,"company":"The Center for Applied Health Sciences, LLC","sponsor":"Brightseed, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Piperine","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"The Center for Applied Health Sciences, LLC","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The Center for Applied Health Sciences, LLC \/ Brightseed, Inc","highestDevelopmentStatusID":"1","companyTruncated":"The Center for Applied Health Sciences, LLC \/ Brightseed, Inc"},{"orgOrder":0,"company":"Jantar","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"JT-1","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Jantar","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jantar \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Jantar \/ Inapplicable"},{"orgOrder":0,"company":"Bioray Laboratories","sponsor":"Shanghai Changzheng Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"BRL-301","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Bioray Laboratories","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bioray Laboratories \/ Shanghai Changzheng Hospital","highestDevelopmentStatusID":"1","companyTruncated":"Bioray Laboratories \/ Shanghai Changzheng Hospital"},{"orgOrder":0,"company":"Bioray Laboratories","sponsor":"First Affiliated Hospital of Zhejiang University","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"BRL-301","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Bioray Laboratories","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bioray Laboratories \/ First Affiliated Hospital of Zhejiang University","highestDevelopmentStatusID":"1","companyTruncated":"Bioray Laboratories \/ First Affiliated Hospital of Zhejiang University"},{"orgOrder":0,"company":"Florida State University","sponsor":"Compound Solutions","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Corebiome","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Florida State University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Florida State University \/ Compound Solutions","highestDevelopmentStatusID":"1","companyTruncated":"Florida State University \/ Compound Solutions"},{"orgOrder":0,"company":"Standard Process Inc.","sponsor":"Nutrasource","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"TPG1","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Standard Process Inc.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Standard Process Inc. \/ Nutrasource","highestDevelopmentStatusID":"1","companyTruncated":"Standard Process Inc. \/ Nutrasource"},{"orgOrder":0,"company":"Shenzhen MagicRNA Biotechnology Co., Ltd","sponsor":"The First Affiliated Hospital of University of Science and Technology of China","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"HN2301","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Shenzhen MagicRNA Biotechnology Co., Ltd","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shenzhen MagicRNA Biotechnology Co., Ltd \/ The First Affiliated Hospital of University of Science and Technology of China","highestDevelopmentStatusID":"1","companyTruncated":"Shenzhen MagicRNA Biotechnology Co., Ltd \/ The First Affiliated Hospital of University of Science and Technology of China"},{"orgOrder":0,"company":"PersonGen BioTherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"CD7 CAR-T Cell","moa":"CD7","graph1":"Immunology","graph2":"Undisclosed","graph3":"PersonGen BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"PersonGen BioTherapeutics \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"PersonGen BioTherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Qualia Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Qualia Senolytic","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Qualia Life Sciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qualia Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Qualia Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Shenzhen MagicRNA Biotechnology Co., Ltd","sponsor":"Songjiang Hospital, Shanghai Jiao Tong University","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"HN2301","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Shenzhen MagicRNA Biotechnology Co., Ltd","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shenzhen MagicRNA Biotechnology Co., Ltd \/ Songjiang Hospital, Shanghai Jiao Tong University","highestDevelopmentStatusID":"1","companyTruncated":"Shenzhen MagicRNA Biotechnology Co., Ltd \/ Songjiang Hospital, Shanghai Jiao Tong University"}]

Find Novel Immunology Drugs in Clinical Development

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Immunology

                          Study Phase : Undisclosed

                          Sponsor : Fidia Farmaceutici Spa

                          Deal Size : Undisclosed

                          Deal Type : Divestment

                          Details : The agreement covers the registrations, trademarks, and related commercial rights of seven products, including four corticosteroids and one non-steroidal anti-inflammatory drug, across Europe and Emerging Markets.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          March 23, 2021

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Immunology

                          Highest Development Status : Undisclosed

                          Sponsor : Fidia Farmaceutici Spa

                          Deal Size : Undisclosed

                          Deal Type : Divestment

                          Sanofi Company Banner

                          02

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          November 12, 2019

                          Lead Product(s) : Upadacitinib

                          Therapeutic Area : Immunology

                          Highest Development Status : Undisclosed

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Abbvie Company Banner

                          03

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          April 16, 2019

                          Lead Product(s) : Risankizumab

                          Therapeutic Area : Immunology

                          Highest Development Status : Undisclosed

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Abbvie Company Banner

                          04

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : The agreement aims to advance Visterra's next-generation biotherapeutic pipeline for immune-mediated and autoimmune diseases, leveraging Nona's proprietary HCAb Harbour Mice technology platform.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          June 12, 2025

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Immunology

                          Highest Development Status : Undisclosed

                          Sponsor : Visterra

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          05

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : OSE will develop novel RNA therapeutics and delivery methods to fine-tune immune responses in inflammatory disorders and autoimmune diseases, leveraging the advantages of RNA-based therapy.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          May 21, 2025

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Immunology

                          Highest Development Status : Undisclosed

                          Sponsor : Inside Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          06

                          Shenzhen MagicRNA Biotechnology Co., Ltd

                          Country arrow
                          Pharmaconex
                          Not Confirmed

                          Shenzhen MagicRNA Biotechnology Co., Ltd

                          Country arrow
                          Pharmaconex
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          May 11, 2025

                          Lead Product(s) : HN2301

                          Therapeutic Area : Immunology

                          Highest Development Status : Undisclosed

                          Sponsor : Songjiang Hospital, Shanghai Jiao Tong University

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Qualia Life Sciences

                          Country arrow
                          Pharmaconex
                          Not Confirmed

                          Qualia Life Sciences

                          Country arrow
                          Pharmaconex
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          May 01, 2025

                          Lead Product(s) : Qualia Senolytic

                          Therapeutic Area : Immunology

                          Highest Development Status : Undisclosed

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          Tongji Hospital

                          Country arrow
                          Pharmaconex
                          Not Confirmed

                          Tongji Hospital

                          Country arrow
                          Pharmaconex
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Inapplicable

                          March 30, 2025

                          Lead Product(s) : Equecabtagene Autoleucel

                          Therapeutic Area : Immunology

                          Highest Development Status : Undisclosed

                          Sponsor : IASO Bio

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          Wecare Probiotics Co., Ltd.

                          Country arrow
                          Pharmaconex
                          Not Confirmed

                          Wecare Probiotics Co., Ltd.

                          Country arrow
                          Pharmaconex
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Probiotic

                          Upfront Cash : Inapplicable

                          March 20, 2025

                          Lead Product(s) : Probiotic

                          Therapeutic Area : Immunology

                          Highest Development Status : Undisclosed

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          Wecare Probiotics Co., Ltd.

                          Country arrow
                          Pharmaconex
                          Not Confirmed

                          Wecare Probiotics Co., Ltd.

                          Country arrow
                          Pharmaconex
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Probiotic

                          Upfront Cash : Inapplicable

                          March 20, 2025

                          Lead Product(s) : Probiotic

                          Therapeutic Area : Immunology

                          Highest Development Status : Undisclosed

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank